Answers are grounded in this paper and cite their sources.
The nitroimidazole prodrugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis , but clinical evidence is limited to date. We selected pretomanid-resistant M. tuberculosis mutants in two mouse models of TB using a range of pretomanid doses. The frequency of spontaneous resistance was approximately 10 −5 CFU.
No takes yet. Share an insight, caveat, or question.
Rifat et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: